This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Karmanos Cancer Center Launches Lung Cancer Screening Program To Help Detect Lung Cancer Early

DETROIT, July 22, 2013 /PRNewswire-USNewswire/ -- The Barbara Ann Karmanos Cancer Center is launching a Lung Cancer Screening Program for adults with a history of smoking – both current and former smokers. The goal of the program is to help detect lung cancer early with the help of low-dose CT (computed tomography) scans. Karmanos is able to offer the lung cancer screening for the reduced cost of $100, thanks to the generous support of the Gianni Ferrarotti Lung Cancer Foundation which is partially underwriting the expense. 



The National Lung Screening Trial (NLST), a study of over 50,000 current or former heavy smokers conducted by the National Institutes of Health, showed that screening using three annual CT scans can reduce the number of deaths from lung cancer. Studies show that, among high-risk adults, early detection of lung cancer through screening with a CT scan rather than a chest X-ray can reduce cancer death by 20 percent and overall death rate by seven percent.

"The findings from this national study are significant, which is why we want to provide this lung cancer screening here at Karmanos," said Shirish Gadgeel, M.D., leader of the thoracic multidisciplinary team at the Karmanos Cancer Institute. He added, "The multidisciplinary Thoracic Oncology team at Karmanos, consisting of experts focused only on lung cancer, is uniquely qualified to implement this important screening program. We are very grateful for the incredible support of the Gianni Ferrarotti Lung Cancer Foundation and the fund created at Karmanos to help put an end to this disease. This screening test is an opportunity to dramatically change the lung cancer mortality rate for those who have a long history of smoking."

Founded in 2004, the Gianni Ferrarotti Lung Cancer Foundation is dedicated to increasing lung cancer awareness and supporting research that will lead to early detection and better treatment options. The foundation has raised more than $70,000 for the Gianni Ferrarotti Lung Cancer Research Fund at Karmanos and has also provided monetary support to numerous families who are in financial need, due to the impact of lung cancer.

Lung cancer is one of the deadliest types of cancer and accounts for more deaths than any other cancer in both men and women. It's estimated that more than 159,400 people will die of lung cancer in the United States this year alone, representing about 27 percent of all cancer deaths. Any opportunity to help prevent this disease or detect it early through screening can result in less extensive treatment and better outcomes, and may help reduce mortality rates.

Who is Eligible for Lung Cancer Screening?
  • Men and women ages 55-75 who are current or former smokers and who've smoked at least one pack of cigarettes a day for 30 years. The NLST found that people in this age range with a history of smoking were most likely to benefit from this screening.

What's Involved?
  • The screening involves three consecutive annual CT scans of the chest. The screening scans are available at the Karmanos Cancer Center Weisberg Cancer Treatment Center in Farmington Hills.
  • Karmanos will offer the initial lung cancer screening test for $100. Should there be a positive finding, future scans should be covered by insurance, otherwise the remaining two scans would also be charged the reduced out-of-pocket cost of $100 each.                  
  • Any abnormality found on the CT should be followed up by the patient's primary health care provider or a specialist at the Karmanos Cancer Center.

To participate in Karmanos' Lung Cancer Screening Program, call toll free 855-527-LUNG (855-527-5864) or email

Another Option

For those who feel the lung cancer screening would be beneficial but do not meet the eligibility criteria or cannot commit financially to complete the program, the INHALE Study could be an option. INHALE (Inflammation, Health and Lung Epidemiology), sponsored by the National Cancer Institute and coordinated by the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine (WSU SOM), is a study that includes a chest CT scan. INHALE is aimed at identifying genetic and environmental determinants of lung disease – gaining understanding about why some people develop lung health problems and others do not. Karmanos and WSU SOM received the national grant to conduct the study with 4,000 participants.  

The INHALE Study serves as another option and may identify cancer in its early stage when it's most treatable. For more information or to enroll in the INHALE Study, call toll free 1-866-828-2339.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%
YHOO $27.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs